Cryoprecipitate prepared from plasma treated with methylne blue plus light: Increasing the fibrinogen concentration

Transfusion Medicine

Volumn 14, Issue 5, 2004, Pages 369-374

  Hornsey, Valerie S ^a   Young, D A ^b   Docherty, A ^b   Hughes, W ^b   Prowse, C V ^a  

^a SCOTTISH NATIONAL BLOOD TRANSFUSION SERVICE   (United Kingdom)

^b West of Scotland Deanery   (United Kingdom)

Author keywords

Cryoprecipitate; Fibrinogen; Methylene blue; Virus inactivation

Indexed keywords

ANTIGEN; BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 8; COLLAGEN; FIBRINOGEN; METHYLENE BLUE; RISTOCETIN COFACTOR; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR;

ARTICLE; ASSAY; BLOOD STORAGE; CONTROLLED STUDY; CRYOPRECIPITATE; CRYOPRECIPITATION; HUMAN; LIGHT; PLASMA; VALIDATION PROCESS; VIRUS INACTIVATION;

BLOOD COAGULATION; FACTOR VIII; FIBRINOGEN; FIBRONECTINS; HUMANS; LIGHT; METHYLENE BLUE; PLASMA;

EID: 8144222749     PISSN: 09587578     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0958-7578.2004.00528.x     Document Type: Article

References (12)

1. Brown, J.E. & Bosak, J.O. (1986) An ELISA test for the binding of von Willebrand antigen to collagen. Thrombosis Research, 43, 303-311.
2. Farrugia, A. & Prowse, C. (1985) Studies on the procurement of blood coagulation factor VIII: effects of plasma freezing rate and storage conditions on cryoprecipitate quality. Journal of Clinical Pathology, 38, 433-437.
3. Foster, P.R., Dickson, A.J., McQuillan, T.A., Dickson, I.H., Keddie, S. & Watt, J.G. (1982) Control of large scale plasma thawing for recovery of cryoprecipitate Factor VIII. Vox Sanguinis, 42, 180-189.
4. Garwood, M., Cardigan, R.A., Drummond, O., Hornsey, V.S., Turner, C.P., Young, D., Williamson, L.M. & Prowse, C.V. (2003) The effect of methylene blue photo-inactivation and methylene blue removal on the quality of fresh frozen plasma. Transfusion, 43, 1238-1247.
5. Guidelines for the Blood Transfusion Services in the United Kingdom. (2002), 6th edn. Stationery Office, London.
6. Hornsey, V.S., Drummond, O., Young, D., Docherty, A. & Prowse, C.V. (2001b) A potentially improved approach to methylene blue virus inactivation of plasma: the Maco Pharma Maco-Tronic system. Transfusion Medicine, 11, 31-36.
7. Hornsey, V.S., Krailadsiri, P., Macdonald, S., Seghatchian, J., Williamson, L. M. & Prowse, C.V. (2000) Coagulation factor content of cryoprecipitate prepared from methylene blue plus light virus-inactivated plasma. British Journal of Haematology, 109, 665-670.
8. Hornsey, V., Young, D. & Prowse, C. (2001a) Cryoprecipitate prepared from methylene blue treated fresh plasma. Transfusion, 41, 151-152.
9. Inada, Y., Hessel, B. & Blomback, B. (1978) Photooxidation of fibrinogen in the presence of methylene blue and its effect on polymerization. Biochimica et biophysica acta, 532, 161-170.
10. Newman, J., Johnson, AJ., Karpatkin, M. & Puszkin, S. (1971) Methods for the production of clinically effective intermediate and high purity factor VIII concentrate. British Journal of Haematology, 21, 1-20.
11. Over, J., Bouma, B.N. & van Mourik, J.A., Sixma, J.J., Vlooswijk, R. & Bakker-Woudenberg, I. (1978) Heterogeneity of human factor VIII. I. Characterization of factor VIII present in the supernatant of cryoprecipitate. The Journal of Laboratory and Clinical Medicine, 91, 32-46.
12. Suontaka, A.M., Blomback, M. & Chapman, J. (2003) Changes in functional activities of plasma fibrinogen after treatment with methylene blue and red light. Transfusion, 43, 568-575.